FDA Inspection
GlaxoSmithKline Biologicals SAGlaxoSmithKline Biologicals SA – FDA Inspection, Jan 27, 2017
Record Details
This FDA Inspection record concerns GlaxoSmithKline Biologicals SA, with an inspection on January 27, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · 70cb7ce5-0715-4ec4-8b61-c997bb03b824
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1007184
- FDA center
- Biologics
- Project area
- Vaccines and Allergenic Products
- Outcome
- Form 483 issued
Other FDA inspections of GlaxoSmithKline Biologicals SA
6| Date | Classification | Office | Project area |
|---|---|---|---|
| February 27, 2026 | Not classified | Office of Inspections and Investigations | |
| June 23, 2023 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| June 24, 2019 | Not classified | Office of Inspections and Investigations | |
| October 2, 2014 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| October 5, 2012 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
Other documents for GlaxoSmithKline Biologicals SA
- FDA Inspection 1304664 - 2026-02-27
- FDA Inspection 1215345 - 2023-06-23
- FDA Inspection 1099397 - 2019-06-24
- FDA Inspection 900625 - 2014-10-02
- FDA Inspection 818683 - 2012-10-05
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.